The Dana-Farber/Harvard Cancer Center (DF/HCC) Breast Cancer Program seeks to gain a better understanding of breast cancer prevention, risk assessment, epidemiology, genetics and molecular biology, with the hope of translating these findings into meaningful prevention strategies for women at risk of breast cancer and new treatment approaches for those diagnosed with the disease. With the recognition of biologically and clinically distinct breast cancer subtypes, the Breast Cancer Program has increasingly focused on subtypes of the disease. In the next five years, substantive contributions are anticipated in the molecular characterization and treatment of triple-negative disease, HER2+ disease and hormone receptor positive disease. The Program will continue to focus on the development of targeted treatment strategies within molecular subtypes and identify mechanisms of drug resistance. The Breast Cancer Program has been continuously approved by the NCI as an Established Research Program since the inception of the Center. At the time of the last competitive renewal, the Program received """"""""outstanding"""""""" merit. The 110 members span all seven DF/HCC institutions and represent 15 departments of HMS and two departments of HSPH. Members currentiy have $28.7 million in peer-reviewed funding (TC), of which neariy $18 million is from NCI. At the time of the prior competitive renewal, peer-reviewed funding was $16 million, of which $10.1 million was from NCI. This funding total includes several new grants including a V Foundation Award, a Stand Up 2 Cancer award that crosses multiple institutions within and outside of DF/HCC and a Susan G. Komen for the Cure Promise Grant focused on prevention. Program members have published 891 papers during the project period of which 17% were intra-programmatic, 38% were inter-programmatic and 24% were interinstitutional, which reflects a high level of productivity and collaboration. The funding and publication record reflects the broad research base of the Program collaboration among breast cancer researchers.

Public Health Relevance

The DF/HCC Breast Cancer Program is dedicated to reducing the burden from breast cancer by reducing the incidence, morbidity and mortality of the disease. This overarching goal will be achieved through strong multidisciplinary collaboration. The Program seeks to understand the complex biological underpinnings of the disease and apply this knowledge to the design of clinical trials and to clinical practice.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Mills, Evanna L; Pierce, Kerry A; Jedrychowski, Mark P et al. (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560:102-106
Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583

Showing the most recent 10 out of 411 publications